Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.
2003 | 2002 | 2001 | 2000 | 1999
12/06/1999
Results of Four ZEVALIN Clinical Studies Presented At ASH
12/04/1999
New Data From Key Rituxan Clinical Studies Presented At 41st Annual Society of Hematology Meeting
12/01/1999
IDEC Pharmaceuticals Announces 2-for-1 Common Stock Split
11/08/1999
10/18/1999
10/04/1999
IDEC Pharmaceuticals Begins Phase I/II Study in Psoriasis With PRIMATIZED Antibody, IDEC-114